Summary & Overview
HCPCS Level II Q4129: Unite biomatrix, per square centimeter
HCPCS Level II code Q4129 denotes a per-square-centimeter billing unit for Unite biomatrix, an extracellular matrix product used in wound management and tissue repair. As biologic grafts and advanced wound therapies become more common, accurate coding for unit-based products like Q4129 matters for clinical documentation, supply-chain management, and payer adjudication at a national level.
Key national payers in typical analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides a concise reference to how Q4129 is defined, where the product is typically used, and what stakeholders should expect when encountering unit-based biomaterial supply codes.
Readers will find benchmarks and contextual guidance on topics that often accompany product codes: common sites of service for application, clinical contexts in which a biomatrix may be used, and typical billing considerations such as unit-of-service reporting. The report also highlights areas where policy updates or payer-specific coverage rules commonly affect reimbursement and documentation requirements.
Data not available in the input for detailed payer policies, modifiers, taxonomies, ICD-10 mappings, and related codes.
Billing Code Overview
HCPCS Level II code Q4129 represents the product Unite biomatrix, per square centimeter. This code describes a square-centimeter unit of a biomatrix product used in tissue repair and regenerative procedures.
-
Service type: Application of a biologic extracellular matrix graft for wound or tissue repair
-
Typical site of service: Hospital outpatient departments, ambulatory surgery centers, wound care clinics, and physician offices
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a chronic non-healing lower extremity wound (e.g., diabetic foot ulcer or venous stasis ulcer) referred to a wound care clinic or outpatient surgical practice for advanced biologic dressing application. The clinical workflow begins with wound assessment: history, vascular and infectious evaluation, wound measurement, debridement if indicated, and optimization of glucose control and infection management. After sharp or enzymatic debridement and appropriate hemostasis, the clinician selects a biosynthetic scaffold product such as Unite biomatrix. The product is cut to size and applied directly to the prepared wound bed, secured with secondary dressings and offloading as required. Follow-up visits occur at regular intervals (typically 1–2 weeks) to assess incorporation, address exudate, change dressings, and determine need for re-application. Typical sites of service include outpatient wound care centers, hospital outpatient departments, ambulatory surgical centers, and sometimes skilled nursing facilities for patients requiring on-site wound management.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
GA | Waiver of liability statement on file | Use when the provider has a signed Advance Beneficiary Notice for expected noncovered services, if applicable |
GB |